Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Minority Interest (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Minority Interest for 3 consecutive years, with -$919000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Minority Interest fell 1.88% year-over-year to -$919000.0, compared with a TTM value of -$919000.0 through Sep 2024, down 1.88%, and an annual FY2023 reading of -$928000.0, down 41.46% over the prior year.
  • Minority Interest was -$919000.0 for Q3 2024 at Oramed Pharmaceuticals, down from -$911000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at -$126000.0 in Q1 2022 and bottomed at -$928000.0 in Q4 2023.
  • Average Minority Interest over 3 years is -$763090.9, with a median of -$891000.0 recorded in 2023.
  • The sharpest move saw Minority Interest crashed 552.38% in 2023, then dropped 1.88% in 2024.
  • Year by year, Minority Interest stood at -$656000.0 in 2022, then crashed by 41.46% to -$928000.0 in 2023, then grew by 0.97% to -$919000.0 in 2024.
  • Business Quant data shows Minority Interest for ORMP at -$919000.0 in Q3 2024, -$911000.0 in Q2 2024, and -$918000.0 in Q1 2024.